title: Tumorgrafts as in vivo surrogates for women with ovarian cancer.
abstract: OBJECTIVE
  Ovarian cancer has a high recurrence and mortality rate. A barrier to improved outcomes includes a lack of accurate models for preclinical testing of novel therapeutics.
  
  
  METHODS
  Clinically relevant, patient-derived tumorgraft models were generated from sequential patients and the first 168 engrafted models are described. Fresh ovarian, primary peritoneal, and fallopian tube carcinomas were collected at the time of debulking surgery and injected intraperitoneally into severe combined immunodeficient mice.
  
  
  RESULTS
  Tumorgrafts demonstrated a 74% engraftment rate with microscopic fidelity of primary tumor characteristics. Low-passage tumorgrafts also showed comparable genomic aberrations with the corresponding primary tumor and exhibit gene set enrichment of multiple ovarian cancer molecular subtypes, similar to patient tumors. Importantly, each of these tumorgraft models is annotated with clinical data and for those that have been tested, response to platinum chemotherapy correlates with the source patient.
  
  
  CONCLUSIONS
  Presented herein is the largest known living tumor bank of patient-derived, ovarian tumorgraft models that can be applied to the development of personalized cancer treatment.
authors.affiliation: Authors' Affiliations: Departments of Oncology, Radiation Oncology, and Molecular Pharmacology and Experimental Therapeutics; Department of Health Sciences Research, Division of Biomedical Statistics and Informatics; Division of Gynecologic Surgery; Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; and Women's Cancer Program, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
authors.forename: S John
authors.initials: SJ
authors.lastname: Weroha
authors.forename: Marc A
authors.initials: MA
authors.lastname: Becker
authors.forename: Sergio
authors.initials: S
authors.lastname: Enderica-Gonzalez
authors.forename: Sean C
authors.initials: SC
authors.lastname: Harrington
authors.forename: Ann L
authors.initials: AL
authors.lastname: Oberg
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Maurer
authors.forename: Sarah E
authors.initials: SE
authors.lastname: Perkins
authors.forename: Mariam
authors.initials: M
authors.lastname: AlHilli
authors.forename: Kristina A
authors.initials: KA
authors.lastname: Butler
authors.forename: Sarah
authors.initials: S
authors.lastname: McKinstry
authors.forename: Stephanie
authors.initials: S
authors.lastname: Fink
authors.forename: Robert B
authors.initials: RB
authors.lastname: Jenkins
authors.forename: Xiaonan
authors.initials: X
authors.lastname: Hou
authors.forename: Kimberly R
authors.initials: KR
authors.lastname: Kalli
authors.forename: Karin M
authors.initials: KM
authors.lastname: Goodman
authors.forename: Jann N
authors.initials: JN
authors.lastname: Sarkaria
authors.forename: Beth Y
authors.initials: BY
authors.lastname: Karlan
authors.forename: Amanika
authors.initials: A
authors.lastname: Kumar
authors.forename: Scott H
authors.initials: SH
authors.lastname: Kaufmann
authors.forename: Lynn C
authors.initials: LC
authors.lastname: Hartmann
authors.forename: Paul
authors.initials: P
authors.lastname: Haluska
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D014408:Biomarkers, Tumor; D002869:Chromosome Aberrations; D016000:Cluster Analysis; D055028:Comparative Genomic Hybridization; D004195:Disease Models, Animal; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006085:Graft Survival; D064593:Heterografts; D006801:Humans; D051379:Mice; D008875:Middle Aged; D060787:Neoplasm Grading; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D014463:Ultrasonography; D023041:Xenograft Model Antitumor Assays
chemical_list: D014408:Biomarkers, Tumor